The Company possesses a growing portfolio of specialty enzyme products and unique technical and operational capabilities designed to enable the production of low-cost, biomass-derived sugars.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
If someone could explain to me exactly what the deal is with these convertible notes, and if the management somehow could give the market some long term guidance, I would be very happy to invest.Verenium seems a bargain at $25.98M. Their technology platform seems exiting, the products they have developed seems good and the enzyme market is one of the most exiting I could think of, and I mean the accumulated deficit of approximately $630.0 million, Was that just money out the window?But then again, if the company is as bad at selling their products as they are at selling the idea of investing in their shares to private investors as my self, maybe verenium shares are heading for 0.Verenium just seems to be one of those companies that is not that investor friendly and where you ask yourself, are this really a public company?I'm giving Verenium the green thumb in hope of that others will take a look at the company and sharing their views.
hmmm. -14.78% to $1.73 thats a lot because of this news:
Jefferies reiterated its Hold rating on Verenium Corporation (NASDAQ: VRNM). At the same time, Jefferies lowered its price target on the company's stock from $2.95 to $2.20.
By Emily Austin
Benzinga Staff Writer
June 08, 2011 8:04 AM
Someone flushed 33.765 shares at the last minute. I've picked up. It's a gamble. I have no idea if this is the buttom. It seems a total flush out rigth now, but if Verenium is profitable in 2013 with moderate stock dilution this is way to cheap, and if they can grow at the same pace as the overall enzyme market from then on, this could easily be a 10 bagger before 2020.
"Someone flushed 33.765 shares at the last minute"
at 1.61
Listened to their investor day webcast again. It seems very promising. I believe a double digit annual revenue growth the next 10 years is possible. But how are they gonna get the $30M they need to get to their goals in a non dilutive way? For a company with a Mkt Cap of <$20M a takeover would seem more likely.